226 related articles for article (PubMed ID: 34572953)
1. Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases.
Bethlehem MS; Katsarelias D; Olofsson Bagge R
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572953
[TBL] [Abstract][Full Text] [Related]
2. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.
Tong TML; Samim M; Kapiteijn E; Meijer TS; Speetjens FM; Brüning R; Schroeder TH; El-Sanosy S; Maschke H; Wacker FK; Vogel A; Dewald CLA; Goeman JJ; Burgmans MC
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1304-1313. PubMed ID: 35922562
[TBL] [Abstract][Full Text] [Related]
3. Survival and Quality of Life after Isolated Hepatic Perfusion with Melphalan as a Treatment for Uveal Melanoma Liver Metastases - Final Results from the Phase III Randomized Controlled Trial SCANDIUM.
Olofsson Bagge R; Nelson A; Shafazand A; All-Eriksson C; Cahlin C; Elander N; Gustavsson A; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Mattsson J; Rizell M; Sternby Eilard M; Ullenhag GJ; Nilsson JA; Ny L; Lindnér P
Ann Surg; 2024 Feb; ():. PubMed ID: 38420778
[TBL] [Abstract][Full Text] [Related]
4. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).
Olofsson Bagge R; Nelson A; Shafazand A; All-Eriksson C; Cahlin C; Elander N; Helgadottir H; Kiilgaard JF; Kinhult S; Ljuslinder I; Mattsson J; Rizell M; Sternby Eilard M; Ullenhag GJ; Nilsson JA; Ny L; Lindnér P
J Clin Oncol; 2023 Jun; 41(16):3042-3050. PubMed ID: 36940407
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience.
Dewald CLA; Warnke MM; Brüning R; Schneider MA; Wohlmuth P; Hinrichs JB; Saborowski A; Vogel A; Wacker FK
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008282
[TBL] [Abstract][Full Text] [Related]
6. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
[TBL] [Abstract][Full Text] [Related]
7. Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit.
Olofsson R; Cahlin C; All-Ericsson C; Hashimi F; Mattsson J; Rizell M; Lindnér P
Ann Surg Oncol; 2014 Feb; 21(2):466-72. PubMed ID: 24141377
[TBL] [Abstract][Full Text] [Related]
8. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver.
Noter SL; Rothbarth J; Pijl ME; Keunen JE; Hartgrink HH; Tijl FG; Kuppen PJ; van de Velde CJ; Tollenaar RA
Melanoma Res; 2004 Feb; 14(1):67-72. PubMed ID: 15091197
[TBL] [Abstract][Full Text] [Related]
9. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.
Hughes MS; Zager J; Faries M; Alexander HR; Royal RE; Wood B; Choi J; McCluskey K; Whitman E; Agarwala S; Siskin G; Nutting C; Toomey MA; Webb C; Beresnev T; Pingpank JF
Ann Surg Oncol; 2016 Apr; 23(4):1309-19. PubMed ID: 26597368
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma.
Estler A; Artzner C; Bitzer M; Nikolaou K; Hoffmann R; Hepp T; Hagen F; Eigentler T; Forschner A; Grözinger G
Acta Radiol; 2022 May; 63(5):577-585. PubMed ID: 34034537
[TBL] [Abstract][Full Text] [Related]
11. Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma.
Dewald CLA; Hinrichs JB; Becker LS; Maschke S; Meine TC; Saborowski A; Schönfeld LJ; Vogel A; Kirstein MM; Wacker FK
Rofo; 2021 Aug; 193(8):928-936. PubMed ID: 33535258
[TBL] [Abstract][Full Text] [Related]
12. Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres.
de Leede EM; Burgmans MC; Kapiteijn E; Luyten GP; Jager MJ; Tijl FG; Hartgrink HH; Grünhagen DJ; Rothbarth J; van de Velde CJ; Verhoef C; Vahrmeijer AL
Melanoma Res; 2016 Dec; 26(6):588-594. PubMed ID: 27513071
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study.
Vogl TJ; Koch SA; Lotz G; Gebauer B; Willinek W; Engelke C; Brüning R; Zeile M; Wacker F; Vogel A; Radeleff B; Scholtz JE
Cardiovasc Intervent Radiol; 2017 Jun; 40(6):864-872. PubMed ID: 28144756
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.
Dewald CLA; Becker LS; Maschke SK; Meine TC; Alten TA; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Clin Exp Metastasis; 2020 Dec; 37(6):683-692. PubMed ID: 33034815
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study.
Meijer TS; Burgmans MC; de Leede EM; de Geus-Oei LF; Boekestijn B; Handgraaf HJM; Hilling DE; Lutjeboer J; Vuijk J; Martini CH; van Erkel AR; van der Meer RW; Tijl FGJ; Speetjens FM; Kapiteijn E; Vahrmeijer AL
Ann Surg Oncol; 2021 Feb; 28(2):1130-1141. PubMed ID: 32761328
[TBL] [Abstract][Full Text] [Related]
16. Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.
Tong TML; van der Kooij MK; Speetjens FM; van Erkel AR; van der Meer RW; Lutjeboer J; van Persijn van Meerten EL; Martini CH; Zoethout RWM; Tijl FGJ; Blank CU; Burgmans MC; Kapiteijn E
Trials; 2022 Feb; 23(1):137. PubMed ID: 35152908
[TBL] [Abstract][Full Text] [Related]
17. Quality of Life Analysis of Patients Treated with Percutaneous Hepatic Perfusion for Uveal Melanoma Liver Metastases.
Tong TML; Fiocco M; van Duijn-de Vreugd JJ; Lutjeboer J; Speetjens FM; Tijl FGJ; Sitsen ME; Zoethout RWM; Martini CH; Vahrmeijer AL; van der Meer RW; van Rijswijk CSP; van Erkel AR; Kapiteijn E; Burgmans MC
Cardiovasc Intervent Radiol; 2024 Jun; 47(6):741-750. PubMed ID: 38587534
[TBL] [Abstract][Full Text] [Related]
18. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma.
Modi S; Gibson T; Vigneswaran G; Patel S; Wheater M; Karydis I; Gupta S; Takhar A; Pearce N; Ottensmeier C; Stedman B
Melanoma Res; 2022 Apr; 32(2):103-111. PubMed ID: 35254333
[TBL] [Abstract][Full Text] [Related]
19. Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study.
Kolb M; Forschner A; Artzner C; Grözinger G; Said I; Dittmann H; Seith F
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894309
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
